A Nationwide Survey for the Management of Neutropenic Fever in Korea 947 guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Kreb- sgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): S105-17. 3. Biron P, Fuhrmann C, Escande MC, Blanc-Vincent MP, Crokaert F, Beal J, Bussy V, Lesimple T, Pottecher B, Raveneau J, Senet JM, Viot M. Standards, Options, and Recommendations for the man- agement of brief neutropenias. Federation Nationale des Centres de Lutte Contre le Cancer. Bull Cancer 1998; 85: 695-711. 4. Viscoli C, Castagnola E, Caniggia M, De Sio L, Garaventa A, Giacchi- no M, Indolfi P, Izzi GC, Manzoni P, Rossi MR, Santoro N, Zanaz- zo GA, Masera G. Italian guidelines for the management of infec- tious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology 1998; 55: 489-500. 5. Proceedings of the consensus meeting: evidence-based recommen- dations on the management of febrile neutropenia in Japan. Hon- olulu, Hawaii, 8-9 March 2003. Clin Infect Dis 2004; 39(Suppl 1): S1-69. 6. Song YG, Chang KH, Kim HY, Hong SK, Park YS, Cho JH, Kim CO, Huh AJ, Park ES, Kim YS, Choi YW, Kim JM. Evaluation for appropriateness of therapeutic use of antibiotics in patients with respiratory tract infections and in patients with febrile neutropenia. J Korean Soc Chemother 2000; 18: 125-40. 7. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibi- otic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95. 8. Hori S, Sunley R, Tami A, Grundmann H. The Nottingham Staphy- lococcus aureus Population Study: prevalence of MRSA among the elderly in a university hospital. J Hosp Infect 2002; 50: 25-9. 9. Yoo JH, Huh DH, Choi JH, Shin WS, Kang MW, Kim CC, Kim DJ. Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis 1997; 25: 1385-91. 10. Lee DG, Choi SM, Choi JH, Yoo JH, Park YH, Kim YJ, Lee S, Min CK, Kim HJ, Kim DW, Lee JW, Min WS, Shin WS, Kim CC. Selec- tive bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med 2002; 17: 38-44. 11. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglyco- side containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002; 2: 231-42. 12. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003; 326: 1111. 13. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neu- tropenic cancer patients. J Clin Oncol 2000; 18: 3038-51. 14. Vidal L, Paul M, Ben-Dor I, Pokroy E, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 2004; 4: CD003992. 15. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC), International Antimi- crobial Therapy Cooperative Group and the National Cancer Insti- tute of Canada-Clinical Trials Group. Vancomycin added to empiri- cal combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991; 163: 951-8. 16. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical antibi- otics against Gram-positive infections for febrile neutropenia: sys- tematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2005; 55: 436-44. 17. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Boden- steiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-71. 18. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402. 19. Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, Oakhill A, Pamphilon DH, Robinson SP, Totem A, Valencia AM, Marks DI. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol 2003; 123: 114-8. 20. Mousset S, Hermann S, Klein SA, Bialleck H, Duchscherer M, Bomke B, Wassmann B, Bohme A, Hoelzer D, Martin H. Prophy- lactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005; 84: 734-41. 21. Price TH. Granulocyte transfusion: current status. Semin hematol 2007; 44: 15-23. 22. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Shin WS, Kang MW. Efficacies and safeties on granulocyte transfusion for severe infec- tions during neutropenic fever. Infect Chemother 2004; 36(S2): S153.